Enhancing Facial Projection: Efficacy and Safety of a Novel Filler Combining Cross‐Linked Sodium Hyaluronate Gel With Poly‐L‐Lactic Acid‐b‐PEG Microspheres for T‐Zone Augmentation

DOI: 10.1111/jocd.70003 Publication Date: 2025-03-23T08:41:39Z
ABSTRACT
ABSTRACTBackgroundThe nose, eyebrow, and forehead are critical elements of the T‐zone, vital for enhancing facial three‐dimensionality. Many Asians seek a more contoured and sculpted facial appearance by T‐zone augmentation. The novel poly‐L‐lactic acid microsphere and hyaluronic acid suspension (PLLA‐b‐PEG/HA) has proven to be a safe and effective dermal filler, making it an appealing choice for individuals aiming for T‐zone augmentation.ObjectiveTo retrospectively assess the efficacy and safety of PLLA‐b‐PEG/HA injection into the T‐zone for aesthetic enhancement.MethodsFifteen participants were included in this study. A comprehensive clinical evaluation was performed, including measurements of total facial convexity angle and radix height, the FACE‐Q scales for satisfaction with the nose, forehead, and eyebrows, the Global Aesthetic Improvement Scale (GAIS), and a 7‐item satisfaction scale. Tissue in the peri‐eyebrow area was examined 12 months posttreatment for comparison with normal tissues.ResultsSignificant increases in radix height and total facial convexity angle were observed at each follow‐up visit (p < 0.05). FACE‐Q scores also showed significant improvements from baseline in the eyebrows, forehead, and nose at each posttreatment visit (p < 0.001). The GAIS improvement rate remained high, with 80.00% reported by participants and 86.67% by blinded evaluators 12 months after treatment. The satisfaction rate was 73.3% at this time interval. Pathological examinations demonstrated newly formed collagen fibers and microvessels, with no abnormal pathological structure.ConclusionThe PLLA‐b‐PEG/HA demonstrates efficacy in enhancing the T‐zone (nose, eyebrow, and forehead) with a favorable safety profile.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (28)
CITATIONS (0)